Display options
Cite
Neufeld MY, Mawassi F, Levy A, et al. Transdermal physostigmine-absence of effect on topographic brain mapping. Behav Neurol. 1993;6(1):33-5doi: 10.3233/BEN-1993-6105.
Neufeld, M. Y., Mawassi, F., Levy, A., Treves, T. A., & Korczyn, A. D. (1993). Transdermal physostigmine-absence of effect on topographic brain mapping. Behavioural neurology, 6(1), 33-5. https://doi.org/10.3233/BEN-1993-6105
Neufeld, M Y, et al. "Transdermal physostigmine-absence of effect on topographic brain mapping." Behavioural neurology vol. 6,1 (1993): 33-5. doi: https://doi.org/10.3233/BEN-1993-6105
Neufeld MY, Mawassi F, Levy A, Treves TA, Korczyn AD. Transdermal physostigmine-absence of effect on topographic brain mapping. Behav Neurol. 1993;6(1):33-5. doi: 10.3233/BEN-1993-6105. PMID: 24487928.
Copy Download .nbib Format: NLM
Share it on

Behav Neurol. 1993;6(1):33-5. doi: 10.3233/BEN-1993-6105.

Transdermal physostigmine-absence of effect on topographic brain mapping.

Behavioural neurology

M Y Neufeld, F Mawassi, A Levy, T A Treves, A D Korczyn

Affiliations

  1. Department of Neurology, Tel-Aviv Sourasky Medical Center and Sackler School of Medicine, Israel.
  2. Israel Institute for Biological Research, Ness Ziona, Israel.

PMID: 24487928 DOI: 10.3233/BEN-1993-6105

Abstract

Nine patients with primary degenerative dementia (PDD) participated in an open trial of transdermal physostigmine (TPh). In order to evaluate the neurophysiologic effects of TPh, EEG data were recorded and compared at baseline and following 2 months of continuous treatment. There was no significant effect of TPh on EEG spectra in patients with PDD.

Keywords: Alzheimer's disease; Brain mapping; Dementia; EEG; Physostigmine

Publication Types